| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/10/2014 | US20140193363 Novel benzimidazole derivatives |
| 07/10/2014 | US20140193361 Systemic glucose tolerance in type-2 diabetes |
| 07/10/2014 | US20140193356 Compositions Comprising Citrate And Applications Thereof |
| 07/10/2014 | US20140193355 Dermal protector |
| 07/10/2014 | US20140193347 Lipid depot formulations |
| 07/10/2014 | US20140193346 Health supplement |
| 07/10/2014 | US20140193335 Devices and methods for the treatment of cancer |
| 07/10/2014 | US20140193334 Targeted Delivery and Prodrug Designs for Platinum-Acridine Anti-Cancer Compounds and Methods Thereof |
| 07/10/2014 | US20140190866 Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material |
| 07/09/2014 | EP2752488A2 Antisense design |
| 07/09/2014 | EP2752422A1 Stereoselective synthesis of phosphorus containing actives |
| 07/09/2014 | EP2752417A1 Spiro-oxindole compounds and their uses as therapeutic agents |
| 07/09/2014 | EP2752416A1 Novel mangromicin compound and production method therefor |
| 07/09/2014 | EP2752415A1 Fluorinated ligands for targeting peripheral benzodiazepine receptors |
| 07/09/2014 | EP2752414A1 Crystalline form of apixaban |
| 07/09/2014 | EP2752413A1 Quinazoline derivative and application thereof |
| 07/09/2014 | EP2752412A1 Intermediates for the synthesis of Argatroban monohydrate |
| 07/09/2014 | EP2752411A1 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders |
| 07/09/2014 | EP2752410A1 Heterocycle derivative having pgd2 receptor antagonist activity |
| 07/09/2014 | EP2752406A1 Substituted pyridazine derivatives which have histamine H3 antagonist activity |
| 07/09/2014 | EP2752404A1 Cysteine protease inhibitors |
| 07/09/2014 | EP2752201A1 C-terminal HSP90 inhibitors to treat pituitary adenomas |
| 07/09/2014 | EP2752191A1 Compositions and methods using hdm2 antagonist and mek inhibitor |
| 07/09/2014 | EP2752190A1 Method for improving therapy for autoimmune diseases such as rheumatoid arthritis |
| 07/09/2014 | EP2752189A1 Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
| 07/09/2014 | EP2752188A1 Adhesive patch |
| 07/09/2014 | EP2752116A1 Natural preservative alternatives comprising lonicera extract and compositions containing same |
| 07/09/2014 | EP2751271A1 Modulators of mir-323-3p for the prevention or treatment of rheumatoid arthritis |
| 07/09/2014 | EP2751120A1 Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| 07/09/2014 | EP2751119A1 Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| 07/09/2014 | EP2751118A1 Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
| 07/09/2014 | EP2751117A2 Metalloenzyme inhibitor compounds |
| 07/09/2014 | EP2751116A1 Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| 07/09/2014 | EP2751115A1 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
| 07/09/2014 | EP2751114A1 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines |
| 07/09/2014 | EP2751112A2 Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| 07/09/2014 | EP2751111A1 Pyrrolobenzodiazepines |
| 07/09/2014 | EP2751110A1 Pyrrolobenzodiazepines |
| 07/09/2014 | EP2751109A1 Heterocyclylamines as pi3k inhibitors |
| 07/09/2014 | EP2751108A1 Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
| 07/09/2014 | EP2751107A1 Compounds and compositions as pdgfr kinase inhibitors |
| 07/09/2014 | EP2751106A1 Substituted annellated pyrimidine and the use thereof |
| 07/09/2014 | EP2751105A1 Compounds and compositions as c-kit kinase inhibitors |
| 07/09/2014 | EP2751104A1 Compounds and compositions as c-kit kinase inhibitors |
| 07/09/2014 | EP2751103A1 Compounds and compositions as c-kit kinase inhibitors |
| 07/09/2014 | EP2751102A1 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS |
| 07/09/2014 | EP2751101A1 Compounds useful as inhibitors of choline kinase |
| 07/09/2014 | EP2751099A1 Compounds useful as inhibitors of atr kinase |
| 07/09/2014 | EP2751097A2 Processes for making compounds useful as inhibitors of atr kinase |
| 07/09/2014 | EP2751096A2 Guanidinyl-substituted polyamides useful for treating human papilloma virus |
| 07/09/2014 | EP2751095A2 Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| 07/09/2014 | EP2751094A1 Novel crystal form |
| 07/09/2014 | EP2751093A1 Heterocyclic compounds and uses thereof |
| 07/09/2014 | EP2751092A1 Selective and reversible inhibitors of ubiquitin specific protease 7 |
| 07/09/2014 | EP2751091A2 Products for anti-inflammation support |
| 07/09/2014 | EP2751090A1 Aldh-2 inhibitors in the treatment of addiction |
| 07/09/2014 | EP2751088A1 Compounds useful as inhibitors of atr kinase |
| 07/09/2014 | EP2751084A1 Pyrimidine carboxamide derivatives |
| 07/09/2014 | EP2751083A1 Quinolone compound |
| 07/09/2014 | EP2751081A1 Polymorphic form of pitavastatin calcium |
| 07/09/2014 | EP2751080A1 Novel soft rock inhibitors |
| 07/09/2014 | EP2751079A1 Biphenylcarboxamides as rock kinase inhibitors |
| 07/09/2014 | EP2751078A1 Novel rock kinase inhibitors |
| 07/09/2014 | EP2751076A1 Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| 07/09/2014 | EP2751071A2 Fatty acid amides, compositions and methods of use |
| 07/09/2014 | EP2750768A1 Decitabine derivative formulations |
| 07/09/2014 | EP2750715A2 Identification of small molecules that enhance therapeutic exon skipping |
| 07/09/2014 | EP2750710A1 Use of compositions having a low polyamine content in the prevention or treatment of adverse effects linked to cancer treatment |
| 07/09/2014 | EP2750699A1 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| 07/09/2014 | EP2750683A1 Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds |
| 07/09/2014 | EP2750681A1 Branched discrette peg constructs |
| 07/09/2014 | EP2750680A1 Method and composition for treating lice infestation |
| 07/09/2014 | EP2750679A1 Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| 07/09/2014 | EP2750678A1 Antibacterial compounds and methods for use |
| 07/09/2014 | EP2750677A1 Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 07/09/2014 | EP2750676A1 Methods and compositions for treating nephrogenic diabetes insipidus |
| 07/09/2014 | EP2750675A1 Synergistic combinations of pi3k- and mek-inhibitors |
| 07/09/2014 | EP2750674A1 Limited release lingual thioctic acid delivery systems |
| 07/09/2014 | EP2750673A1 Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride |
| 07/09/2014 | EP2750672A1 Use of organic compound for the treatment of noonan syndrome |
| 07/09/2014 | EP2750671A2 Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| 07/09/2014 | EP2750670A1 Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| 07/09/2014 | EP2750668A1 Formulations and dosage forms of oxidized phospholipids |
| 07/09/2014 | EP2750666A1 Multi-layered release formulation |
| 07/09/2014 | EP2750665A1 Oral formulations containing hyaluronic acid for sustained drug release |
| 07/09/2014 | EP2750664A1 Levothyroxine formulations |
| 07/09/2014 | EP2750660A2 Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| 07/09/2014 | EP2750523A1 Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| 07/09/2014 | EP2750505A1 Antibacterial compounds and methods for use |
| 07/09/2014 | CN103917647A 用于神经保护的方法和组合物 A method for neuroprotection and compositions |
| 07/09/2014 | CN103917550A 用于制备替诺福韦的方法 Methods for the preparation of tenofovir |
| 07/09/2014 | CN103917545A Btk抑制剂 Btk inhibitor |
| 07/09/2014 | CN103917544A 氯吡格雷的分阶段给药 Phased administration of clopidogrel |
| 07/09/2014 | CN103917541A 抗病毒化合物 Antiviral compounds |
| 07/09/2014 | CN103917540A 抗细菌的哌啶基取代的3，4-二氢-1h-[1，8]萘啶酮 Antibacterial piperidinyl substituted 3,4-dihydro -1h- [1,8] naphthyridine-one |
| 07/09/2014 | CN103917539A 2-氧代-噁唑烷-3,5-二基抗生素衍生物 2-oxo - oxazolidine-3,5-diyl antibiotic derivative |
| 07/09/2014 | CN103917538A 2-(1,2,3-三唑-2-基)苯甲酰胺及3-(1,2,3-三唑-2-基)吡啶酰胺衍生物 2- (1,2,3-triazol-2-yl) benzamide, and 3- (1,2,3-triazol-2-yl) pyridine amide derivative |
| 07/09/2014 | CN103917536A 1-吡唑基-3-(4-((2-(苯氨基嘧啶-4-基)氧基)萘-1-基)用作p38 MAP激酶抑制剂 1-pyrazolyl-3- (4 - ((2- (phenylamino-pyrimidin-4-yl) oxy) naphthalen-1-yl) used as a p38 MAP kinase inhibitors |
| 07/09/2014 | CN103917535A 吡唑化合物和其药物用途 Pyrazole compounds and their pharmaceutical use |
| 07/09/2014 | CN103917534A 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物 As h3 receptor inhibitors urethane containing piperidine and piperazine rings / urea derivative |